Zimmer Biomet Holdings (ZBH) Tops Q4 EPS by 2c, Beats on Revenue; Offers FY26 EPS Guidance

Zimmer Biomet Holdings (NYSE: ZBH) reported Q4 EPS of $2.42, $0.02 better than the analyst estimate of $2.40. Revenue for the quarter came in at $2.24 billion versus the consensus estimate of $2.22 billion.

GUIDANCE:

Zimmer Biomet Holdings sees FY2026 EPS of $8.30-$8.45, versus the consensus of $8.47.

For earnings history and earnings-related data on Zimmer Biomet Holdings (ZBH) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Meta plans to build prediction markets app called Arena - NYT
• Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary